Chairman Choo Chee Kong Buys $60.5K More CytoMed Shares, Stake Rises to 24.92%
GDTC sits 19% above its 52-week low of $0.68.
Summary
Chairman Choo Chee Kong acquired 62,000 CytoMed shares for ~$60.5K in open market purchases between October 5-8, 2026, raising his stake to 24.92%.
Key Events · Ownership and Investor Activity · GDTC
-
Chairman Buys 62,000 Shares
Choo Chee Kong acquired 62,000 ordinary shares in open market purchases between October 5-8, 2026, for approximately $60,554.03 at prices ranging from $0.8805 to $1.0458 per share.
-
Stake Rises to 24.92%
His beneficial ownership increased to 2,974,746 shares, representing 24.92% of 11,934,908 outstanding shares, up from 24.3% previously disclosed.
-
Purchases Amid Nasdaq Deficiency
The buying occurred during the same period the company received a Nasdaq minimum bid price deficiency notice on October 6, 2026, and follows going concern language disclosed in the September 30, 2026 6-K.
-
Continued Insider Accumulation
This follows his $300,000 purchase in July 2026 at $1.50 per share, showing sustained personal-fund conviction despite the stock trading below $1.00.
Analysis · GDTC · Life Sciences
Chairman Choo Chee Kong purchased 62,000 shares for approximately $60,554 between October 5-8, 2026, increasing his beneficial ownership to 24.92% of outstanding shares. The purchases come at a critical juncture — the company received a Nasdaq minimum bid price deficiency notice on October 6, 2026, and disclosed going concern language in its September 30, 2026 6-K. The Chairman's continued accumulation with personal funds, following his $300,000 purchase in July 2026, demonstrates conviction despite the listing and financial distress risks.
How filings like this one have moved
In the 30 days to Oct 13, 2026, 29.1% of the 1500 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.51%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GDTC was trading at $0.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.6M. The 52-week trading range was $0.68 to $3.68. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.